Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to
inflammation of the skin. Therapies spread over the skin may not be enough to control the AD
in trial participants who require systemic anti-inflammatory treatment. This study compares
upadacitinib to dupilumab in adolescent and adult participants with moderate to severe AD who
have inadequate response to systemic therapies. Adverse events and change in the disease
activity will be assessed.
Upadacitinib and dupilumab are approved drugs for the treatment of moderate to severe atopic
dermatitis (AD). The study is comprised of a 35-day Screening Period, a 16-week treatment
period 1 and a 16-week treatment period 2. During period 1, participants are randomly
assigned in 1 of 2 groups, called treatment arms to receive upadacitinib Dose A or dupilumab.
In Period 2, participants will receive upadacitinib Dose A or Dose B. Approximately 880
adolescent and adult participants ages 12 to 64 with moderate to severe AD who are candidates
for systemic therapy will be enrolled at up to 330 sites worldwide.
Participants will receive upadacitinib oral tablets once daily or dupilumab as per its label
for 32 weeks and followed for 30 days.
There may be higher treatment burden for participants in this trial compared to their
standard of care . Participants will attend regular visits during the study at a hospital or
clinic. The effect of the treatment will be checked by medical assessments, blood tests,
checking for side effects and completing questionnaires.

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Tulsa

Vital Prospects Clinical Research Institute, PC /ID# 249840

Upadacitinib

Dupilumab

A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects With Moderate to Severe Atopic Dermatitis (Level-Up)

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in
the acute treatment of moderate or severe migraine in children and adolescents.

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Lynn Institute of Tulsa

Rimegepant/BHV3000

Matching placebo

Phase 3, Multicenter, Randomized, Double-blind,Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age

The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in
the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to
11 and 12 to 17 years.

A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Ps0007 50212

Certolizumab pegol

Placebo

Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)

The purpose of the study is to assess the safety and tolerability of UCB0599 and to
demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of
disease progression over 12 and 18 months in participants diagnosed with early-stage
Parkinson's Disease.

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

Pd0053 50398

UCB0599

A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease

This phase III trial studies how well lenalidomide in combination with ixazomib works
compared to lenalidomide alone in treating patients with evidence of residual multiple
myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of
multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better
than giving lenalidomide alone in treating patients with evidence of residual multiple
myeloma after a stem cell transplantation.

Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Oklahoma Cancer Specialists and Research Institute-Tulsa

Ixazomib Citrate

Lenalidomide

Placebo Administration

Quality-of-Life Assessment

Questionnaire Administration

Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of
BLU-5937 in participants with Refractory Chronic Cough (RCC).

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Vital Prospects Clinical Research Institute, P.C.

BLU-5937

A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough

The primary objectives of the study are:
-  To longitudinally characterize the long-term effectiveness of DUPIXENT® through
assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related
to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities,
and their change over-time.
-  To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting with
respect to their medical history, demographic and disease characteristics, and type 2
comorbidities
The secondary objectives of the study are:
-  To characterize real-world utilization of DUPIXENT® for patients with CRSwNP
-  To collect patient and physician global assessment of disease severity and treatment
satisfaction for patients receiving DUPIXENT® for CRSwNP
-  To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Essential Medical Research

DUPIXENT®

Assessing Long-Term Outcomes of DUPIXENT® Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyposis (AROMA)

This study is done to find out whether the medicine, semaglutide, has a positive effect on
early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not
contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have
17 clinic visits and 1 phone call with the study doctor. The study includes various tests and
scans. At 10 of the clinic visits participants will have blood samples taken.
Participants must have a study partner, who is willing to take part in the study.
Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study
period.
A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study
will be performed on a selection of sites based on their experience with CSF sampling and
willingness to participate in this sub-study. The endpoints related to this sub-study are
exploratory only.

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

Novo Nordisk Investigational Site

Semaglutide

Placebo (semaglutide)

A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus)

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Semagludtide

A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive
therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Central States Research, LLC

Troriluzole

A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Tulsa, Oklahoma

Tulsa

< 0 mi

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

< 0 mi

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

< 0 mi

A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)

< 0 mi

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

< 0 mi

Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

< 0 mi

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

< 0 mi

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

< 0 mi

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

< 0 mi

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

< 0 mi

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder